Nexxa.ai | $4,400,000 | (Jul 22, 2025)
Litero AI | $800,000 | (Jul 22, 2025)
Ovasave | $1,200,000 | (Jul 22, 2025)
Vicebio
United Kingdom
- Londres, Angleterre, Royaume-Uni
- 24/09/2024
- Series B
- $100,000,000
Vicebio uses the molecular clamp technology to develop innovative vaccines against life-threatening respiratory viruses. The Molecular Clamp technology provide unique stabilisation of viral envelop glycoproteins making possible highly effective, ready-to-use, and multivalent single shot respiratory virus vaccines.
- Industry Biotechnology Research
- Website https://vicebio.com/
- LinkedIn https://www.linkedin.com/company/vicebio/
Related People
Emmanuel HanonFounder
Belgium -
Brussels Metropolitan Area
Research & Development leader, C-level Executive, with more than 20 years experience at GSK, last 7 years running the global vaccines RD for GSK. Led the discovery and development of five major Vaccines : Quadrivalent Influenza (Fluarix and Flulaval Quadrivalent), Shingles (Shingrix), Malaria (Mosquirix), RSV older adult, and MenABCWY 5-in-1 Vaccines.
Broad functional leadership experience includes R&D, medical, clinical, regulatory, technical CMC, manufacturing and quality operations. Expert in Immunology, Microbiology, and Vaccinology
Radical AI | $55,000,000 | (Jul 22, 2025)
LeadStory | $2,750,000 | (Jul 22, 2025)
Xelix | $160,000,000 | (Jul 22, 2025)
Toduba | $4,090,457 | (Jul 22, 2025)
Alix | $20,000,000 | (Jul 22, 2025)
WattCarbon | Undisclosed Amount | (Jul 18, 2025)
Occupi | $3,000,000 | (Jul 18, 2025)
Folio | $14,000,000 | (Jul 18, 2025)
BQP(US) | $5,000,000 | (Jul 18, 2025)